Earnings Releases·Nov 4, 2026, 4:24 PM ET

OPKO Health — Third Quarter 2026 Earnings Summary

Consolidated revenue rose 16% year-over-year to $65.4 million, driven by a Global Products segment operating income turnaround to $6.0 million from a $1.2 million loss; however, net loss from continuing operations widened to $35.5 million ($0.05/share) from $33.0 million ($0.04/share).
The company withdrew guidance for services revenue and total costs/expenses due to uncertainty surrounding the pending Labcorp transaction, while reaffirming full-year 2026 total revenue guidance of $268.0 million to $278.0 million.
Strategic progress includes the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash plus up to $150 million in contingent consideration, alongside the initiation of Phase 1/2a trials for OPK-8801001 and OPK-88006.
Capital activities included raising $123.1 million via senior secured royalty financing linked to Eli Lilly's mazdutide revenue and repurchasing 7.05 million shares for $10.6 million, leaving $84.3 million available under the $200 million authorization.